Cancers, Vol. 13, Pages 332: CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

Cancers, Vol. 13, Pages 332: CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives Cancers doi: 10.3390/cancers13020332 Authors: Michela Roberto Antonio Astone Andrea Botticelli Luisa Carbognin Alessandra Cassano Giuliana D’Auria Agnese Fabbri Alessandra Fabi Teresa Gamucci Eriseld Krasniqi Mauro Minelli Armando Orlandi Francesco Pantano Ida Paris Laura Pizzuti Ilaria Portarena Nello Salesi Simone Scagnoli Paola Scavina Giuseppe Tonini Patrizia Vici Paolo Marchetti Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype, and endocrine therapy (ET) remains its therapeutic backbone. Although anti-estrogen therapies are usually effective initially, approximately 50% of HR+ patients develop resistance to ET within their lifetime, ultimately leading to disease recurrence and limited clinical benefit. The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to ET have remarkably improved the outcome of patients with HR+ advanced breast cancer (ABC) compared with anti-estrogens alone, by targeting the cell-cycle machinery and overcoming some aspects of endocrine resistance. However, which patients are the better candidates for these drugs, which are the mai...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research